Compositions for lice control

Through a single oral frerana treatment, the problem of low control of infestation of sheep lice in the prior art was solved, effective protection of long-haired sheep was achieved, environmental pollution and treatment frequency were reduced, and animal welfare was improved. Productivity.

CN114786484BActive Publication Date: 2024-11-19INTERVET INT BV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080084557.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-12-16
Filing Date
2020-12-15
Publication Date
2024-11-19
Estimated Expiration
2040-12-15

AI Technical Summary

Technical Problem

The prior art is difficult to effectively and for a long-term control of Bovicola ovis infection, especially in long-haired sheep. Conventional local treatments are inefficient and require frequent repetition, resulting in environmental pollution and animal discomfort.

Method used

Isoxazoline compounds, especially frerana, are employed to provide effective treatment and protection of sheep lice by single oral administration, independent of the wool length, avoiding labor-intensive and environmental pollution of local administration.

Benefits of technology

Long-term control and protection of sheep lice is achieved, the frequency of treatment is reduced, the environmental exposure to insecticides is reduced, and animal welfare and production efficiency is improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114786484B_ABST
    Figure CN114786484B_ABST
Patent Text Reader

Abstract

The present invention relates to a method for treating or preventing chewing lice infestation in sheep animals by oral administration of an isoxazoline compound of formula (I).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the treatment or prevention of parasitic arthropod infestations in animals. Background Art

[0002] Sheep lice are a major problem in the sheep industry in Australia and New Zealand.

[0003] Such lice that infest sheep are generally classified as sucking lice that feed directly on the blood of the host sheep and biting or chewing lice that feed generally on dead skin, secretions and bacteria found on the surface of the skin. Three species of sucking lice are known on sheep - Linognathus pedalis, L. africanus and L. ovillus.

[0004] However, in all major sheep producing countries including Australia and New Zealand, the biting or chewing louse (Bovicola ovis) is the most common and economically important louse species infesting sheep. Sheep body lice are obligate parasites and complete their entire life cycle on sheep. They typically feed on dead skin, secretions and bacteria found on the surface of the skin and move within the wool depending on temperature.

[0005] The main source of infection in sheep is contact with infected sheep. Infection is spread by direct contact, for example when sheep are kept in sheep yards or sheds or gathered in resting / shaded areas.

[0006] Throughout the year, the size of individual sheep's lice populations fluctuates depending on the season and the time of shearing. Lice populations are lowest in the summer immediately after shearing and peak in mid-winter. Shearing significantly reduces the size of lice populations through physical removal and subsequent exposure to environmental conditions. Intense ultraviolet light and very high wool temperatures reduce lice populations.

[0007] Lice can irritate infested sheep, causing friction which can lead to damaged wool and poor wool growth, as well as causing discomfort and annoyance to the animals. In addition, flies may attack damaged and wet areas of wool on infested animals.

[0008] Lice infestations can cause significant production losses in sheep in two ways:

[0009] 1. Wool damage: Lice cause intense irritation. Infested sheep bite themselves or rub against trees and fences, which causes wool disorder, hair loss or fiber breakage. Lice-infested wool usually has a yellow color and a characteristic odor caused by skin secretions, leading to further degradation.

[0010] 2. Hidden Lesions: Lice can trigger an immune response called cockle, which causes thickening of the skin and damage to the fur.

[0011] In addition to direct economic costs, the continued use of conventional treatments to control lice infestations can have detrimental effects on farmer safety through the entry of residues from such treatments (particularly residual dips or other fluids containing pesticide residues) into the environment and food chain.

[0012] Conventional methods of controlling lice include chemicals applied as dips, sprays, sprays and pour-ons, which kill lice by contact. All sheep body lice treatments currently registered in the major markets of Australia and New Zealand (2019) are topically applied treatments with active ingredients from the following chemical classes: neonicotinoids (imidacloprid, thiacloprid), spinosads (spinosad), organophosphates (OP: temephos, diazinon), macrolides (ML: abamectin, ivermectin), magnesium fluosilicate / sulphur (MgFSi, sulphur, rotenone), insect growth regulators (IGR: diflubenzuron, triflumuron), and synthetic pyrethroids (SP: cypermethrin, cis-cypermethrin, deltamethrin).

[0013] These products are applied by following conventional topical methods.

[0014] Backline application: A relatively small amount of product is applied along the sheep's back from head to rump. From here, the chemical diffuses over the body surface, aided by contact between sheep.

[0015] Immersion (plunge and cage) dipping: In this treatment, the sheep is completely immersed in a dipping solution. Effective lice control relies on wetting the entire body of the sheep to skin level; this can be very difficult due to the waterproofing effect of wool.

[0016] Shower Dipping: Shower dipping relies on applying a large amount of dipping wash from a nozzle on a slowly rotating boom to completely wet the sheep.

[0017] Hand Spraying: Hand spraying is a method used for lice treatment in long wool (wool growing for more than 6 weeks). Hand spraying requires high pressure to be applied at the hand piece to allow the liquid to penetrate the wool.

[0018] However, lice problems often re-emerge in affected flocks after treatment because the small number of surviving lice begin to multiply and farmers may notice sheep scratching, biting, pulling out their wool or becoming infested when sheared. Thus, due to the limited efficacy of conventional topical application methods, frequent retreatment is required, which requires additional treatment of the animals, increases pesticide use and harms the environment. Therefore, there is a great need in the sheep industry for an easily applied lice treatment that effectively controls or eliminates existing lice infestations and prevents reinfestation.

[0019] Bayer's International Patent Applications WO 2013 / 184006 and WO 2014 / 051440 suggest internal / systemic administration of spinosad compounds (spinosad) or neonicotinoid compounds (thiacloprid) to control chewing lice. However, long-term effective treatment of chewing lice infestations has not been shown in the literature, even under laboratory conditions, and multiple high doses need to be applied over time to show adequate therapeutic effect, and no protective effect against new lice infestations has been demonstrated. To date, there are no products on the market for oral administration to sheep to control biting / chewing lice. Therefore, none of the prior art methods meet the needs of sheep producers.

[0020] Therefore, there is a need in the art to find better solutions to the problem of controlling chewing lice infestations in the sheep industry without harming the animals, the environment or people. Summary of the invention

[0021] The present invention provides a novel method and composition for controlling chewing / biting lice in sheep independent of the length of their fleece.

[0022] Therefore, in one embodiment, the present invention relates to the use of an isoxazoline compound of formula (I) or a salt thereof or a solvate thereof in the preparation of a medicament,

[0023]

[0024] in

[0025] R 1 Halogen, CF3, OCF3, CN,

[0026] n is an integer from 0 to 3 including 3, preferably 1, 2 or 3,

[0027] R 2 is C1-C3-haloalkyl, preferably CF3 or CF2Cl,

[0028] T is a 5-12 membered monocyclic or bicyclic ring system, which is optionally substituted by one or more groups Y,

[0029] Y is methyl, halomethyl, halogen, CN, NO2, NH2-C≡S, or two adjacent groups Y together form a chain, especially a three-membered or four-membered chain;

[0030] Q is X-NR 3 R 4 NR 5 -NR 6 -XR 3 , X-R3 or a 5-membered N-heteroaryl ring, which is optionally substituted with one or more groups;

[0031] X is CH2, CH(CH3), CH(CN), CO, CS,

[0032] R 3 is hydrogen, methyl, haloethyl, halopropyl, halobutyl, methoxymethyl, methoxyethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, N-phenyl-N-methyl-amino, haloethylaminocarbonylmethyl, haloethylaminocarbonylethyl, tetrahydrofuranyl, methylaminocarbonylmethyl, (N,N-dimethylamino)-carbonylmethyl, propylaminocarbonylmethyl, cyclopropylaminocarbonylmethyl, propenylaminocarbonylmethyl, haloethylaminocarbonylcyclopropyl, alkylsulfanyl, alkylsulfanylalkyl, alkylsulfonylalkyl, cycloalkyl

[0033]

[0034]

[0035] Where Z A is hydrogen, halogen, cyano, halomethyl, preferably CF3;

[0036] R 4 is hydrogen, ethyl, methoxymethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, methoxycarbonyl, methoxymethylcarbonyl, aminocarbonyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, haloethylaminocarbonylmethyl, cyanomethylaminocarbonylmethyl, or haloethylaminocarbonylethyl;

[0037] R 5 is hydrogen, alkyl or haloalkyl;

[0038] R 6 is hydrogen, alkyl or haloalkyl;

[0039] or R 3 and R 4 Together they form a substituent selected from:

[0040]

[0041] The medicament is used to treat or protect sheep from Bovicola ovis infection following a single oral administration of a composition comprising an effective amount of at least one isoxazoline compound of formula (I) to sheep of any fleece length.

[0042] In one embodiment, the present invention provides a composition comprising an effective amount of a compound of formula (I) or a salt or solvate thereof, when used to eliminate chewing lice parasite infestations in sheep and / or for protecting sheep from chewing lice infestations, wherein the composition is administered orally as a single dose to sheep of any wool length.

[0043] In a preferred embodiment, the isoxazoline compound of formula (I) is flurellanil.

[0044] In another preferred embodiment, the composition is applied once more than 6 weeks after shearing.

[0045] Another embodiment is a method of treating sheep diagnosed or suspected of being infested with chewing lice parasites comprising a single oral administration of an effective amount of at least one isoxazoline compound of formula (I) or a salt or solvate thereof to the sheep, regardless of the length of their fleece.

[0046] Another embodiment is a method of protecting sheep from chewing lice infestation comprising a single oral administration of an effective amount of at least one isoxazoline compound of formula (I) or a salt or solvate thereof to the sheep, regardless of the length of their wool. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] Figure 1 Shown is a comparison of plasma concentrations of flurellana (Compound 11-1) after administration of 1 mg / kg bw to beagle dogs using various routes of administration: Group A - PO (Oral), Group B - SC (Subcutaneous), Group C, Group D, Group E - Top- (Topical). The figure is taken from WO2009 / 024541.

[0048] The compositions tested were:

[0049]

[0050] Figure 2 Shown are mean plasma S-flurana concentrations in sheep following single topical, oral and subcutaneous administration at 3 mg / kg bw. DETAILED DESCRIPTION OF THE INVENTION

[0052] It is known that lice infestations can only be successfully and sustainably treated in freshly shorn and short wool sheep, but not in long wool sheep. Existing topline products with long wool treatment claims can only be used as an "emergency treatment" as they are known to only reduce lice burdens and therefore require the animal to be re-treated with a different product at the next shearing. Other prior art methods for topical treatment are impractical in long wool sheep (e.g. soaking and shower dipping) as the long wool prevents effective wetting of the sheep. Therefore, there is a great need for an effective product that can be used on sheep of all wool lengths, including long wool.

[0053] The isoxazoline compounds of formula (I) are known to be effective in controlling blood-sucking parasites such as fleas and ticks, and when oral administration of such compounds is used, long-term efficacy and blood levels can be obtained in treated animals. Figure 1 Shown are the blood concentrations of flurellanil following administration of 1 mg / kg bw to dogs using different routes of administration. Figure 1 It was shown that after oral administration in dogs, effective blood levels were obtained for at least 56 days.

[0054] However, variations in pharmacokinetic profiles between animal species have been found. Background Examples and Figure 2 The plasma concentrations of flurellan following administration of 3 mg / kg bw to sheep using different routes of administration are shown. Figure 1 and Figure 2 It can be clearly seen in the comparison of the results that when comparable doses of flurana are administered to different species, the curves are very different. With regard to oral administration, these figures show that flurana levels in sheep blood drop sharply to below 1 ng / mL 12 days after dosing, while in dogs (with a lower dose of 1 mg / kg bw), effective levels are still present. By 21 days after dosing, all sheep had concentrations below the LLOQ after oral administration.

[0055] Based on this pharmacokinetic profile, it is quite surprising that effective treatment and protection against non-blood-sucking lice in sheep can be obtained using a single oral administration of an effective amount of an isoxazoline compound as described in this application.

[0056] As shown in the examples, lice infestations present in both long-wool sheep and recently shorn sheep can be effectively treated by a single oral administration of an effective amount of an isoxazoline compound of formula (I) as described below, especially flurellanal, to sheep. Currently, sheep are mostly treated recently or when they are short-wool, due to practical management reasons and due to the difficulty in obtaining adequate anti-chewing lice efficacy in long wool. Therefore, the use according to the invention provides an animal welfare benefit by reducing the time that infested animals remain untreated and suffer the discomfort and annoyance caused by lice infestation.

[0057] Additionally, as shown in Example 4, one treatment provided protection of sheep from reinfestation with chewing lice, wherein treated sheep were challenged with lice within 2 weeks of application and no lice infestation was established on treated sheep for more than 12 weeks.

[0058] This was quite unexpected considering the pharmacokinetic profile following oral administration, as the blood levels of the isoxazoline compound flurellana dropped very rapidly following oral administration to sheep, and therefore there was no sustained effect, which is necessary for effective control / eradication, without the need for a long-acting / slow-release formulation to achieve a sustainable effect in sheep following administration of the oral formulation.

[0059] The benefits of this approach are:

[0060] a) This method is more convenient to use on animals than the prior art because it avoids labor-intensive techniques and avoids stress on the sheep animals when using this prior art topical method;

[0061] b) Furthermore, prior art applications of parasiticides raise concerns regarding animal safety and user safety during administration, and sheep can be handled immediately after treatment without exposure to the parasiticide;

[0062] c) the method is easy to use with gavage equipment available, for example, on sheep farms, and therefore requires no or minimal investment in new equipment; and

[0063] d) By this method, sheep can be applied over a defined period of time, regardless of wool length, and thus chewing lice populations can be effectively controlled throughout the flock and production unit even when sequential shearing is used.

[0064] e) The resistance breaking properties of the isoxazoline compounds are very advantageous, ie chewing lice are very sensitive to the inhibitory or killing action of the isoxazoline compounds.

[0065] f) Typically, only a single application is required to effectively control / eliminate an existing chewing lice infestation and there is no need to re-treat wool sheep at the next shearing, thus reducing environmental exposure to harmful pesticides.

[0066] Therefore, by using isoxazoline compounds as described in the present application, the disadvantages of the prior art can be avoided because a single convenient, safer application of the isoxazoline compound will be sufficient to achieve the desired effect.

[0067] The present invention would therefore be a breakthrough in the control of body lice in sheep, allowing for the effective control / elimination of lice from a flock of sheep regardless of the fleece length of the animals.

[0068] definition

[0069] The following definitions are relevant to embodiments of the present invention.

[0070] All references herein to "lice" or "lice" refer to the parasitic sheep body louse (chewing or biting louse), Bovicolaovis, unless specifically stated otherwise.

[0071] "Treating", "treat", "treatment" means applying or administering an isoxazoline compound or composition to an ovine animal diagnosed with an infestation of parasitic chewing lice to eradicate the parasite infestation or to reduce the parasite count in an infested animal. This is a medical service provided to animals infested with ectoparasites (WAAVP Guidelines 2006)

[0072] The effect may be, for example, ovicidal, larvicidal and / or adulticidal or a combination thereof. The effect may be manifested directly, i.e. by killing the parasites immediately or after a period of time, e.g. when molting occurs, or by destroying their eggs, or indirectly, e.g. by reducing the number of eggs laid and / or the hatching rate.

[0073] "Protect" means preventing infestation of new sheep, flocks or herds by killing the adult parasite and any developmental / larval stages that are capable of infecting a host before they infect the host, or by killing or inhibiting the parasites when they infect an animal that has been treated with an isoxazoline compound as previously described, or by preventing the production of progeny of the parasite, for example by reducing the number of eggs laid and / or the hatch rate.

[0074] For example, a protective period may be useful when treated ewes are exposed to untreated lambs, or when treated lambs are exposed to untreated ewes infested with lice, or when treated and untreated sheep are intermixed.

[0075] "Period of protection" is the time expressed in days or weeks after treatment that a veterinary test product will prevent reinfestation of the animal host with ectoparasites. Sometimes called the preventive period or duration of efficacy (WAAVP Guidelines 2006)

[0076] As used herein, an "active pharmaceutical ingredient" (or active ingredient, or pharmaceutically active ingredient or pharmaceutically acceptable active ingredient) is a substance used in a pharmaceutical product that is intended to provide pharmacological activity or otherwise have a direct role in the diagnosis, cure, mitigation, treatment, or prevention of disease, or in restoring, correcting, or altering a physiological function in humans or animals.

[0077] "Single administration" means that only one dose of the isoxazoline compound is administered to the sheep.

[0078] An "effective amount" is the amount or quantity of an isoxazoline compound as described above required to treat or prevent a parasitic chewing lice infestation in an animal, ie, to reduce or decrease the number of lice on an animal and / or inhibit the development of a parasitic infestation on an animal.

[0079] This amount is readily determined by observing or detecting the number of parasites or eggs on the animals before and after application of the isoxazoline compound as described above, e.g., a reduction in parasite counts of 5% to about 100%, preferably more than 50%, more than 70%, more than 90%, more than 95%, more than 99.5% or 100% after the first application. Preferably, the lice count is reduced by 100%, i.e., the effective amount results in the elimination of all lice on the treated animals, i.e., no chewing lice are found when the sheep are examined as described above.

[0080] Depending on the specific isoxazoline compound used, such application allows for complete inhibition or killing of chewing lice and preferably all viable eggs present on the animal.

[0081] In one embodiment, oral administration of an isoxazoline compound as described above results in the elimination / eradication of a chewing lice infestation. According to Australian regulations (Australian Pesticides and Veterinary Medicines Authority (APVMA) guidelines, "eradication" is defined as the removal of all live lice and live eggs from treated animals, as determined by examining sheep 52 weeks after treatment. In current APVMA regulations, this statement applies only to products applied to freshly shorn or short wool. Factors affecting the effective amount may include, for example, the parasite species to be treated and the developmental stage of the parasite, wool length (see more details below), the type of animal infested (e.g., species and breed, fine wool, coarse wool or woolly), age and condition; environmental conditions (temperature, humidity), pharmacological considerations, such as the activity, efficacy, potency, selectivity, pharmacokinetic and toxicological profile of the specific isoxazoline compound administered; and whether the isoxazoline compound administered is part of a combination of active ingredients. Therefore, the preferred amount of the compound according to the present invention may vary.

[0082] Lice infestation is diagnosed by visual inspection of the wool of sheep, particularly those suspected of being infested. Lice can be found on most areas of the wool of the sheep. The density of lice is highest along the sides and sometimes on the back of the sheep. After shearing, a larger proportion of lice are found in the lower body areas such as under the neck, lower abdomen and thighs and in areas where the wool has not been closely sheared.

[0083] To determine the level of lice infestation in sheep, the WAAVP guidelines 2006 (Holdsworth, PA et al.: “World Association for the Advancement of Veterinary Parasitology guidelines for evaluating the efficacy of ectoparasiticids against biting lice, sucking lice and sheep keds on ruminants”, Veterinary Parasitology 136 (2006), 45-54)" stipulates that a total of 40 parts (sections) of about 10 cm width per animal or 80 parts (sections) of about 5 cm width per animal are to be inspected. These parts should be spaced so that they represent the entire area of ​​the body covered by the wool on each side of the sheep. In addition, APVMA recommends that the inspection parts on each side of the animal be divided equally, that is, 20 (10 cm) or 40 (5 cm) parts should be inspected on each side of the body (total = 40 (10 cm) or 80 (5 cm) parts). In addition, APVMA recommends that the number of divisions on each side of the body be equally distributed between the neck, shoulder, withers, hips and flanks, that is, 4 (10 cm) or 8 (5 cm) divisions at each position on each side of the body.

[0084] Sheep are preferably examined for lice infestation and / or the presence of viable eggs 20 weeks after treatment.

[0085] The isoxazoline compounds used in the present invention are known in the art, and these compounds and their use as antiparasitic agents are described, for example, in U.S. Patent Application US 2007 / 0066617 and International Patent Applications WO 2005 / 085216, WO 2007 / 079162, WO 2009 / 002809, WO 2009 / 024541, WO 2009 / 003075, WO 2010 / 070068 and WO 2010 / 079077, the disclosures of which and the references cited herein are incorporated by reference. Such compounds are known to have excellent activity against blood-sucking ectoparasites, i.e. parasitic insects and mites such as ticks and fleas.

[0086] In one example, according to the composition of the present invention, the method or use of the isoxazoline compound of formula (I)

[0087]

[0088] in

[0089] R 1Halogen, CF3, OCF3, CN,

[0090] n is an integer from 0 to 3 including 3, preferably 1, 2 or 3,

[0091] R 2 is C1-C3-haloalkyl, preferably CF3 or CF2Cl,

[0092] T is a 5-12 membered monocyclic or bicyclic ring system, which is optionally substituted by one or more groups Y,

[0093] Y is methyl, halomethyl, halogen, CN, NO2, NH2-C≡S, or two adjacent groups Y together form a chain, especially a three-membered or four-membered chain;

[0094] Q is X-NR 3 R 4 NR 5 -NR 6 -XR 3 , X-R3 or a 5-membered N-heteroaryl ring, which is optionally substituted with one or more groups;

[0095] X is CH2, CH(CH3), CH(CN), CO, CS,

[0096] R 3 is hydrogen, methyl, haloethyl, halopropyl, halobutyl, methoxymethyl, methoxyethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, N-phenyl-N-methyl-amino, haloethylaminocarbonylmethyl, haloethylaminocarbonylethyl, tetrahydrofuranyl, methylaminocarbonylmethyl, (N,N-dimethylamino)-carbonylmethyl, propylaminocarbonylmethyl, cyclopropylaminocarbonylmethyl, propenylaminocarbonylmethyl, haloethylaminocarbonylcyclopropyl, alkylsulfanyl, alkylsulfanylalkyl, alkylsulfonylalkyl, cycloalkyl

[0097]

[0098]

[0099] Where Z A is hydrogen, halogen, cyano, halomethyl, preferably CF3;

[0100] R 4is hydrogen, ethyl, methoxymethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, methoxycarbonyl, methoxymethylcarbonyl, aminocarbonyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, haloethylaminocarbonylmethyl, cyanomethylaminocarbonylmethyl, or haloethylaminocarbonylethyl;

[0101] R 5 is hydrogen, alkyl or haloalkyl;

[0102] R 6 is hydrogen, alkyl or haloalkyl;

[0103] or R 3 and R 4 Together they form a substituent selected from:

[0104]

[0105] or a salt or a solvate thereof.

[0106] In a preferred embodiment of the present invention and / or its embodiments, T is selected from

[0107]

[0108]

[0109] In T-1, T-3 and T-4, the group Y is preferably hydrogen, halogen, methyl, halomethyl, ethyl or haloethyl.

[0110] In a preferred embodiment of the present invention and / or its embodiments, Q in formula (I) is selected from

[0111] Q-9

[0112] Where R 3 , R 4 , X and Z A As defined above and

[0113] Z 8 for

[0114]

[0115]

[0116] Z D for

[0117]

[0118] Preferred compounds of formula (I) are listed in Table 1:

[0119] Table 1:

[0120]

[0121]

[0122]

[0123] More preferred compounds of formula (I) are listed in Table 2.

[0124]

[0125]

[0126]

[0127] In particularly preferred embodiments of the present invention and / or its embodiments, the isoxazoline compound is represented by formula (II)

[0128]

[0129] in

[0130] R 1a , R 1b , R 1c are independently hydrogen, Cl or CF3. Preferably, R 1a and R 1c is Cl or CF3 and R 1b For hydrogen,

[0131] T is

[0132]

[0133] wherein Y is methyl, bromine, Cl, F, CN or C(S)NH2, and

[0134] Q is as above.

[0135] In another preferred embodiment of the present invention and / or its embodiments, R 3 H and R 4 It is -CH2-C(O)-NH-CH2-CF3, -CH2-C(O)-NH-CH2-CH3, -CH2-CH2-CF3 or -CH2-CF3.

[0136] In another preferred embodiment of the present invention and / or its embodiments, the isoxazoline compound is selected from fluralaner, afoxolaner, sarolaner, lotilaner and tigolaner.

[0137] In a preferred embodiment of the present invention and / or its embodiments, the isoxazoline compound is 4-[5-(3,5-dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-2-methyl-N-[(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-benzamide (CAS RN 864731-61-3). The compound is also known as flurella. In a preferred embodiment of the present invention and / or embodiments thereof, the isoxazoline compound is 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2-trifluoroethylamino]ethyl]-1-naphthalene-carboxamide (CAS RN 1093861-60-9). This compound is also known as 4-[5-(5-chloro-α,α,α-trifluoro-m-tolyl)-4,5-dihydro-5-(trifluoromethyl)-1,2-oxazol-3-yl]-N-[2-oxo-2-[(2,2,2-trifluoroethylamino]ethyl]naphthalene-1- or afoxolan. Afoxolan is disclosed, for example, in WO 2007 / 079162.

[0138] In a preferred embodiment of the present invention and / or its embodiment, the isoxazoline compound is 1-(5'-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azetidine-3,1'-isobenzofuran]-1-yl)-2-(methylsulfonyl)ethan-1-one, preferably 1-(5'-((5S)-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-3'H-spiro[azetidine-3,1'-isobenzofuran]-1-yl)-2-(methylsulfonyl)ethan-1-one (CAS RN: 1398609-39-6), which is called sarolana.

[0139] In a preferred embodiment of the present invention and / or its embodiment, the isoxazoline compound is 3-methyl-N-(2-oxo-2-(2,2,2-trifluoroethyl)amino)ethyl)-5-[5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl]thiophene-2-carboxamide, preferably methyl-N-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-5-[(5S)-5(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl]thiophene-2-carboxamide (CAS RN: 1369852-71-0). This compound is called lotirana.

[0140] In a preferred embodiment of the present invention and / or its embodiment, the isoxazoline compound is 2-chloro-N-(1-cyanocyclopropyl)-5-[1-[2-methyl-5-(1,1,2,2,2-pentafluoroethyl)-4-(trifluoromethyl)pyrazol-3-yl]pyrazol-4-yl]benzamide (CAS RN 1621436). This compound is called tigoraner.

[0141] In a preferred embodiment of the present invention and / or embodiments thereof, the isoxazoline compound is (Z)-4-[5-(3,5-dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-N-[(methoxyimino)methyl]-2-methylbenzamide (CAS RN 928789-76-8).

[0142] In a preferred embodiment of the present invention and / or embodiments thereof, the isoxazoline compound is 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-N-(thietan-3-yl)benzamide (CAS RN 1164267-94-0) disclosed in WO2009 / 0080250.

[0143] In a preferred embodiment of the present invention and / or embodiments thereof, the isoxazoline compound is 5-[5-(3,5-dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-3-methyl-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-2-thiophenecarboxamide (CAS RN 1231754-09-8) disclosed in WO 2010 / 070068.

[0144] Particularly preferred is fluororanaline (corresponding to 4-[5-(3,5-dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-2-methyl-N-[(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-benzamide).

[0145] The isoxazoline compound can exist in various isomeric forms. Mentioning isoxazoline compounds always includes all possible isomeric forms of this compound. Unless otherwise stated, the compound structure that does not indicate a specific conformation is intended to cover the composition of all possible conformational isomers of the compound, and the composition that contains less than all possible conformational isomers. In some embodiments, the compound is a chiral compound. In some embodiments, the compound is an achiral compound.

[0146] Method of the present invention (or purposes) comprises and uses racemic mixture, for example the enantiomer of isoxazoline compound as mentioned above of equal amount.In addition, method of the present invention comprises the isoxazoline compound that is rich in the enantiomer of formula (I) compared with racemic mixture.Also comprise the substantially pure enantiomer of this isoxazoline compound.

[0147] When enantiomerically enriched, one enantiomer is present in greater amounts than the other, and the degree of enrichment can be defined by expression of enantiomeric excess ("ee"), which is defined as (2x-1)-100%, where x is the mole fraction of the predominant enantiomer in the mixture (e.g., 20% ee corresponds to a 60:40 ratio of enantiomers). Preferably, the compositions used in the present invention have an enantiomeric excess of at least 50%; more preferably at least 75%; still more preferably at least 90%; and most preferably at least 94% enantiomeric excess of the more active isomer. Of particular note are embodiments in which the more active isomer is enantiomerically pure.

[0148] The isoxazoline compounds described above may contain additional chiral centers. The process of the present invention encompasses racemic mixtures as well as enriched and substantially pure stereoconfigurations at these additional chiral centers.

[0149] For example, isoxazoline contains a chiral (or asymmetric) carbon at the 5-position of the isoxazoline ring. In some embodiments, for example, the chiral carbon has a left-handed (or "S" or "left-handed") configuration. Examples of such compounds are:

[0150]

[0151] In other embodiments, the chiral carbon has a right-handed (or "R" or "rectus") configuration. Examples of such compounds are:

[0152]

[0153] In a preferred embodiment, the active enantiomer (s)-fluralan is used.

[0154] In another preferred embodiment, the active enantiomer (s)-afoxolamide is used.

[0155] Unless otherwise indicated, isoxazoline structures that do not indicate a specific conformation are intended to encompass compositions of all possible conformational isomers of isoxazoline, as well as compositions containing less than all (eg, only one) possible conformational isomers.

[0156] The isoxazoline compounds mentioned in the present specification include enantiomers, salts and solvates thereof which can be prepared by conventional methods.

[0157] The term "salt" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids.

[0158] The term "solvate" is used herein to describe a molecular association comprising one or more pharmaceutically acceptable solvent molecules (eg, water or ethanol). When the solvent is water, the term "hydrate" is used.

[0159] The isoxazoline compounds of formula (I) can be prepared according to one or other methods described in the methods of patent applications US 2007 / 0066617, WO 2007 / 079162, WO 2009 / 002809, WO 2009 / 080250, WO 2010 / 070068, WO 2010 / 079077, WO 2011 / 075591 and WO 2011 / 124998 or any other methods within the capabilities of those skilled in the art (chemical synthesis experts). For the chemical preparation of the products of the present invention, those skilled in the art are considered to have the full content of the "Chemical Abstracts" and the documents cited therein, especially at her / his arrangement.

[0160] In one embodiment of the present invention, an existing chewing lice infestation may be controlled, preferably eliminated within 15 days of application.

[0161] In one embodiment of the invention, no live chewing lice eggs can be found from the treated animals when the sheep are evaluated within 42 days after administration.

[0162] In one embodiment of the invention, after a single application, no live lice and no live eggs are found on the treated animals 140 days after treatment.

[0163] It has also been discovered that the present invention may also be used to control (treat and / or prevent infestation) resistant lice populations in sheep.

[0164] Resistance can be defined as exposure to low doses of an insecticide that allows some lice to survive, and these have genes that allow them to survive higher doses that normally kill all lice. Continued use of the same chemical or group of chemicals allows the resistant lice to survive, reproduce, and increase in number until they constitute the majority of the population. Sometimes, when resistance is present, treatment suppresses lice but does not completely eradicate them. These suppressed infestations are difficult to detect and increase the chances of lice spreading between colonies.

[0165] The present invention can be used on sheep infested with lice that are resistant to any of the organophosphates, pyrethroids, neonicotinoids, spinosad or benzoylphenyl urea compounds and will still provide effective treatment / protection.

[0166] In one embodiment, the present invention is capable of protecting sheep from infestation by chewing lice for at least 2 weeks or 4 weeks.

[0167] Lice infestations that can be treated / prevented by the present invention may be present in various breeds of sheep, including coarse wool sheep and fine wool sheep breeds such as Merino. Sheep breeds are known to have different susceptibilities to lice infestations. The Merino breed appears to be more susceptible than other breeds, but all breeds of sheep, including shedding breeds such as Dorper and Damaras, can carry lice. The present invention works in all of these sheep breeds.

[0168] An important aspect of the invention is that sheep with any length of wool can be successfully treated. This means administration within 24 hours of shearing for fresh shearing or >24 hours after shearing up to 6 weeks after short shearing or >6 weeks after long shearing.

[0169] The present invention can be applied to a single sheep infested with lice or to a flock of sheep having at least one sheep diagnosed as being infested with chewing lice.

[0170] Until now, it has been easier to eradicate sheep lice on a farm with one main shearing than with the nature of shearing at different times (split shearing). The present invention allows successful control of lice infestations even under such conditions, which is a major advantage for managing a sheep farm. Where split shearing occurs, where in the past it was critical that the treated flocks remain separated from the untreated sheep until the untreated sheep are treated at their next shearing, now all sheep can be treated at the same time, regardless of their shearing date.

[0171] In the past, flock management was further complicated in situations where pregnant ewes or ewes with lambs needed to be treated for lice. During this period, there was a potential for lice to spread from ewes to lambs if there was contact with untreated lambs. Once the protective effect of the ewe treatment wore off, and if the lambs were not treated, lice could spread back to the ewes to continue the infestation. This is because backline treatments and insect growth regulator products take some time to cause the death of all lice. During this period, there was a potential for lice to spread if there was contact with other untreated sheep.

[0172] The product labeling of prior art products contains restrictions that apply in this situation, such as a mandatory quarantine period (the time when treated sheep must not mix with untreated sheep). The mandatory quarantine period varies between products but is usually 6 weeks.

[0173] Management of ewes or mothers with lambs is more complicated due to the risk of reinfestation with lambs soon after treatment. In this case in particular it is very advantageous if the product protects the sheep against reinfestation with chewing lice.

[0174] Typical effective (dosage) amounts of isoxazoline compounds, particularly flurana, are between 0.1 mg / kg body weight and 50 mg / kg body weight, or 0.25 mg / kg body weight to 10 mg / kg bw, or 0.5 mg / kg bw to 7.5 mg / kg bw, or 1 to 5 mg / kg bw of the treated animal. In one embodiment, the effective dose is 1.5 mg / kg body weight. In another embodiment, the effective dose is 0.5 mg / kg body weight, particularly when sheep are treated just after shearing. In the case of flurana, particularly preferred is a dose of about 1.5 to about 3 mg / kg body weight of the animal, which has been shown to eliminate lice infestations after a single application, <24 hours after shearing (just sheared) or >24 hours after shearing to 6 weeks after shearing (short hair) or >6 weeks after shearing (long hair).

[0175] Additionally, a single administration may be performed at various time points within the above timeframe without negatively affecting the efficacy of the treatment, thereby allowing flexibility, for example when a large number of sheep need to be treated. In one embodiment, the single administration is within one week prior to shearing the sheep.

[0176] It has been found that a single oral administration of an isoxazoline compound, particularly flurellana, can significantly reduce lice and eggs when given 7 days prior to clipping, within 24 hours after clipping, or 6 weeks after clipping.

[0177] In one embodiment, a single dose of an effective amount of an isoxazoline compound is administered to sheep that have been diagnosed as being infested with chewing lice.

[0178] In one embodiment, a single dose of an effective amount of an isoxazoline compound is administered to sheep that have been in contact with sheep that have been diagnosed with a chewing lice infestation and are therefore at risk of becoming infested.

[0179] It has surprisingly been found that an extended duration of effective control, especially prevention of new lice infestations, is possible without requiring the composition to be an extended release composition to provide effective blood levels of the isoxazoline compound of formula (I) throughout the protection and / or treatment period. In one embodiment, the protection period is 2 weeks. In another embodiment, the protection period is 4 weeks.

[0180] The term "extended release" or "extended release composition" as used herein means a dosage form formulated in such a way that the pharmaceutically active ingredient is available over an extended period of time due to the interaction of a combination of formulation components / excipients and the natural pharmacokinetic or pharmacodynamic characteristics of the active agent(s).

[0181] This definition is consistent with known and accepted usage of the term in the veterinary field, as described in the article "Terminology Challenges: Defining Modified Release Dosage Forms in Veterinary Medicine" by Marilyn N. Martinez, Danielle Lindquist, and Sanja Modric (Journal of Pharmaceutical Sciences, Vol. 99, No. 8, August 2010).

[0182] Many veterinary compositions are known to be suitable for oral administration to animals, but they are different for different animal species. For sheep, usually the active pharmaceutical ingredient is administered orally as a solid (e.g. tablet or pill) or liquid and administered through its feed or drinking water. In large flocks, the use of oral drenches is the most common oral dosage form, especially when administering anthelmintics.

[0183] A drench refers to the administration of a liquid, possibly slightly viscous composition containing the active pharmaceutical ingredient and excipients by mouth, using a special drench gun to dispense the anthelmintic into the sheep's throat.

[0184] Oral drenching compositions will generally be solutions or suspensions and normally not more than 20 ml, preferably not more than 15 ml of such a drenching will be administered per sheep.

[0185] In one embodiment, the concentrated solution is used to administer the isoxazoline compound to sheep by drenching administration.

[0186] In another embodiment, the suspension formulation is for drench application.

[0187] Excipients may comprise conventional inactive pharmaceutically and veterinarily acceptable components, such as fillers, binders, flavoring agents, solvents, colorants, glidants, preservatives, especially solvents, surfactants, stabilizers, such as antioxidants. Pharmaceutical excipients are excipients familiar to those skilled in the art, such as those described in the European Pharmacopoeia.

[0188] combination

[0189] The invention also relates to compositions for use according to the invention comprising more than one pharmaceutically active ingredient, ie wherein the composition for oral administration comprises a further active pharmaceutical ingredient.

[0190] Those of ordinary skill in the veterinary art will be fully familiar with the nature of such active ingredients, which may include, but are not limited to, antiparasitics such as endoparasitics (including anthelmintics) and ectoparasitics, hormones and / or their derivatives, and minerals and vitamins.

[0191] Particularly preferred is the combination with selenium, in particular as sodium selenate.

[0192] The active ingredient is preferably an antiparasitic, and more preferably an endoparasitic, preferably an anthelmintic, and is selected from the group consisting of avermectins (e.g. ivermectin, doramectin, abamectin); milbemycins (moxide and milbemycin); pro-benzimidazoles (e.g. febantel, netobimine and thiophanate); benzimidazole derivatives, such as thiazole benzimidazole derivatives (e.g. thiabendazole and cambendazole), carbamate benzimidazole derivatives (e.g. fenbendazole, albendazole (oxide), mebendazole, oxfendazole, parbendazole, oxibendazole, flubendazole and triclabendazole); imidazothiazoles (e.g. levamisole and tetramisole); tetrahydropyrimidines (morantel and pyrantel), salicylanilides (e.g. closantel, oxyclozanide, rafoxanide and niclosamide); nitrophenol compounds (e.g. nitrobenzonitrile and nitrocyanate); phenyldisulfonamide drugs (e.g. clorsulon); pyrazine isoquinolines (e.g. praziquantel and escitalol); heterocyclic compounds (e.g. piperazine, ethodicarbamazine and phenothiazines); dichlorophen, arsenides (e.g. thioacetamide, meloxamine and arsenamide); cyclic octapeptides (e.g. amodeoside); acetaminophen (e.g. dequent); and aminoacetonitrile compounds (e.g. monepantel, AAD1566); amidine compounds (e.g. amidantel and tripenamidine), including all pharmaceutically acceptable forms, such as salts, solvates or N-oxides.

[0193] Particularly preferred are combinations with moxidectin, levamisole, fenbendazole, avermectin, monepantel, derquent, oxfendazole, albendazole, closantel and combinations thereof, such as those used in the following anthelmintic drenches products commercially available in Australia: Trifecta, Zolvix Plus, Startect, Duocare LV, Cydectin SE, Q-Drench, Tridectin.

[0194] In one embodiment, the compositions of the present invention may be mixed with existing commercial products prior to administration to animals.

[0195] In an alternative embodiment, the composition comprises an effective amount of an isoxazoline compound for controlling chewing lice and a (fixed) combination of another active ingredient for controlling a different parasite infestation (e.g. against parasitic worms or alternatively fly infestation). In a specific embodiment, two isoxazoline compounds as described above for controlling different parasites are included.

[0196] Other combinations of the invention may include ectoparasiticides, such as insect or mite growth regulators (AGR or IGR), for example lufenuron, diflubenzuron, isoflurane, fluazifop, cyromazine, methoprene, pyriproxyfen, dicynilin, etc., neonicotinoids, such as imidacloprid or thiacloprid or spinosads, such as spinosad.

[0197] The amount of each component in the final product can vary significantly depending on the nature of the pharmaceutically active ingredient, the weight and condition of the subject being treated, and the desired unit dose. Based on the teachings of this disclosure, one of ordinary skill in the art will be able to adjust the dosage of a specific pharmaceutically active ingredient in the composition.

[0198] The products of the present invention generally also contain physiologically acceptable formulation excipients known in the art, such as those described in "Gennaro, Remington: The Science and Practice of Pharmacy" (20th edition, 2000), which is incorporated herein by reference. All these ingredients, carriers and excipients must be substantially pharmaceutically or veterinarily pure and non-toxic in the amounts employed, and must be compatible with the pharmaceutically active ingredients.

[0199] The present invention is further described by the following numbered paragraphs:

[0200] 1. Use of an isoxazoline compound of formula (I) or a salt or solvate thereof as described above or in claim 1 for the preparation of a medicament for treating or protecting sheep from infestation by chewing lice following a single oral administration of a composition comprising an effective amount of at least one isoxazoline compound of formula (I) to sheep of any fleece length.

[0201] 2. The use according to paragraph 1, wherein the chewing lice infestation is a Bovicola ovis infestation.

[0202] 3. The use according to paragraph 1 or 2, wherein the isoxazoline compound of formula (I) is flurellanil.

[0203] 4. The use according to any one of paragraphs 1 to 3, wherein the effective amount of the isoxazoline compound is 0.5 or 1.5-3 mg / kg of the animal's body weight.

[0204] 5. The use according to any one of paragraphs 1 to 4, wherein the composition is administered as an oral drench.

[0205] 6. The use according to any of paragraphs 1 to 5, wherein the composition is applied once to a flock of sheep having at least one sheep diagnosed with chewing lice infestation.

[0206] 7. The use according to paragraph 6, wherein the composition is applied once within 24 hours after shearing of the freshly sheared hair.

[0207] 8. The use according to paragraph 6, wherein the composition is applied once within a period of >24 hours after shearing to 6 weeks after shearing.

[0208] 9. The use according to paragraph 6, wherein the composition is applied once > 6 weeks after hair cutting.

[0209] 10. The use according to any of paragraphs 1 to 9, wherein the effective amount of the isoxazoline compound is sufficient to eliminate an existing chewing lice infestation within 15 days of application.

[0210] 11. The use according to any of paragraphs 1 to 9, wherein the effective amount of the isoxazoline compound is sufficient to eliminate viable chewing lice eggs from the treated animal within 42 days after administration.

[0211] 12. The use according to any of paragraphs 1-11, wherein a single application of the effective amount of the isoxazoline compound is sufficient to eliminate all live lice and live eggs from the treated animal 140 days after treatment.

[0212] 13. The use according to any of paragraphs 1 to 12, wherein the effective amount of the isoxazoline compound is sufficient to protect sheep from chewing lice infestation for at least 4 or 2 weeks after a single oral administration.

[0213] 14. The use according to paragraph 13, wherein the effective amount of the isoxazoline compound is sufficient to protect sheep from chewing lice infestation for at least 6 weeks after a single oral administration.

[0214] 15. The use according to any of paragraphs 1 to 14, wherein the chewing louse is resistant to any of organophosphates, synthetic pyrethroids, neonicotinoids, spinosad or benzoylphenyl urea compounds.

[0215] 16. A composition comprising an effective amount of at least one isoxazoline compound of formula (I) as described above, or a salt or solvate thereof, for use in eliminating chewing lice parasite infestations in sheep and / or for protecting sheep from chewing lice infestations, wherein the composition is administered orally to sheep of any fleece length.

[0216] 17. The composition of paragraph 16, wherein the chewing lice infestation is a Bovicola ovis infestation.

[0217] 18. The composition according to paragraph 15 or 16, wherein the isoxazoline compound of formula (I) is flurellanil.

[0218] 19. The composition of any of paragraphs 16-18, wherein the effective amount is 0.5 or 1.5-3 mg / kg of animal body weight.

[0219] 20. The composition of any of paragraphs 16-19, wherein the composition is an oral enema.

[0220] 21. The composition according to any of paragraphs 16-20, wherein the composition is administered once.

[0221] 22. The composition according to paragraph 21, wherein the composition is applied once within 24 hours after shearing.

[0222] 23. The composition of paragraph 21, wherein the composition is applied once >24 to 6 weeks after shearing.

[0223] 24. The composition of paragraph 21, wherein the composition is applied once > 6 weeks after shearing.

[0224] 25. The composition of any of paragraphs 16-24, wherein the effective amount of the isoxazoline compound is sufficient to eliminate an existing chewing lice infestation within 15 days of application.

[0225] 26. The composition of any of paragraphs 16-25, wherein a single application of the effective amount of the isoxazoline compound is sufficient to eliminate all live lice and live eggs from the treated animal 140 days after treatment.

[0226] 27. The composition of any of paragraphs 16-26, wherein the effective amount of the isoxazoline compound is sufficient to protect sheep from chewing lice infestation for at least 4 or 2 weeks following a single oral administration.

[0227] 28. The composition of paragraph 27, wherein the effective amount of the isoxazoline compound is sufficient to protect sheep from chewing lice infestation for at least 6 weeks following a single oral administration.

[0228] 29. The composition of any of paragraphs 16-28, wherein the chewing louse is resistant to any of organophosphates, synthetic pyrethroids, neonicotinoids, spinosad, or benzoylphenyl urea compounds.

[0229] 30. A method of treating sheep diagnosed or suspected of being infested with chewing lice parasites, the method comprising administering to the sheep an effective amount of at least one isoxazoline compound of formula (I) as described above, or a salt or solvate thereof, irrespective of the length of their fleece using a single oral administration.

[0230] 31. The method of paragraph 30, wherein the chewing lice infestation is a Bovicola ovis infestation.

[0231] 32. The method according to paragraph 30 or 31, wherein the isoxazoline compound of formula (I) is flurellanil.

[0232] 33. The method of any of paragraphs 30-32, wherein the effective amount is 0.5 or 1.5-3 mg / kg of the animal's body weight.

[0233] 34. The method of any of paragraphs 30-33, wherein the composition is administered by oral drench.

[0234] 35. The method of any of paragraphs 30-34, wherein the composition is administered once.

[0235] 36. The method of paragraph 35, wherein the composition is applied once within 24 hours of shearing immediately following shearing.

[0236] 37. The method of paragraph 35, wherein the composition is applied once >24 hours after shearing to 6 weeks after shearing.

[0237] 38. The method of paragraph 35, wherein the composition is applied once > 6 weeks after hair shearing.

[0238] 39. The method of any of paragraphs 30-38, wherein the effective amount of the isoxazoline compound is sufficient to eliminate an existing chewing lice infestation within 15 days of administration.

[0239] 40. The method of any of paragraphs 30-39, wherein a single application of the effective amount of the isoxazoline compound is sufficient to eliminate all live lice and live eggs from the treated animal 140 days after treatment.

[0240] 41. The method of any of paragraphs 30-40, wherein the chewing louse is resistant to any of an organophosphate, a synthetic pyrethroid, a neonicotinoid, a spinosad, or a benzoylphenyl urea compound.

[0241] 42. A method of protecting sheep from infestation by chewing lice comprising administering to the sheep, irrespective of the length of their fleece, an effective amount of an isoxazoline compound of formula (I) or a salt or solvate thereof as described above using a single oral administration.

[0242] 43. The method of paragraph 42, wherein the chewing lice infestation is a Bovicola ovis infestation.

[0243] 44. The method according to paragraph 42 or 43, wherein the isoxazoline compound of formula (I) is flurellanil.

[0244] 45. The method of any of paragraphs 42-44, wherein the effective amount is 0.5 or 1.5-3 mg / kg of the animal's body weight.

[0245] 46. ​​The method of any of paragraphs 42-45, wherein the composition is administered orally.

[0246] 47. The method of any of paragraphs 42-46, wherein the composition is administered once.

[0247] 48. The method of paragraph 47, wherein the composition is applied once within 24 hours after shearing.

[0248] 49. The method of paragraph 47, wherein the composition is applied once >24 hours after shearing to 6 weeks after shearing.

[0249] 50. The method of paragraph 47, wherein the composition is applied once > 6 weeks after shearing.

[0250] 51. The method of any of paragraphs 42-50, wherein the effective amount of the isoxazoline compound is sufficient to protect sheep from chewing lice infestation for at least 2 or 4 weeks following a single oral administration.

[0251] 52. The method of paragraph 51, wherein the effective amount of the isoxazoline compound is sufficient to protect sheep from chewing lice infestation for at least 6 weeks following a single oral administration.

[0252] 53. The method of any of paragraphs 42-52, wherein the chewing louse is resistant to any of an organophosphate, a synthetic pyrethroid, a neonicotinoid, a spinosad, or a benzoylphenyl urea compound.

[0253] 54. Use of the isoxazoline compound of formula (I)

[0254]

[0255] in

[0256] R 1 Halogen, CF3, OCF3, CN,

[0257] n is an integer from 0 to 3 including 3, preferably 1, 2 or 3,

[0258] R 2 is C1-C3-haloalkyl, preferably CF3 or CF2Cl,

[0259] T is a 5-12 membered monocyclic or bicyclic ring system, which is optionally substituted by one or more groups Y,

[0260] Y is methyl, halomethyl, halogen, CN, NO2, NH2-C≡S, or two adjacent groups Y together form a chain, especially a three-membered or four-membered chain;

[0261] Q is X-NR 3 R 4 NR 5 -NR 6 -XR 3 , X-R3 or a 5-membered N-heteroaryl ring, which is optionally substituted with one or more groups;

[0262] X is CH2, CH(CH3), CH(CN), CO, CS,

[0263] R 3 is hydrogen, methyl, haloethyl, halopropyl, halobutyl, methoxymethyl, methoxyethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, N-phenyl-N-methyl-amino, haloethylaminocarbonylmethyl, haloethylaminocarbonylethyl, tetrahydrofuranyl, methylaminocarbonylmethyl, (N,N-dimethylamino)-carbonylmethyl, propylaminocarbonylmethyl, cyclopropylaminocarbonylmethyl, propenylaminocarbonylmethyl, haloethylaminocarbonylcyclopropyl, alkylsulfanyl, alkylsulfanylalkyl, alkylsulfonylalkyl, cycloalkyl

[0264]

[0265]

[0266] Where Z A is hydrogen, halogen, cyano, halomethyl, preferably CF3;

[0267] R 4 is hydrogen, ethyl, methoxymethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, methoxycarbonyl, methoxymethylcarbonyl, aminocarbonyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, haloethylaminocarbonylmethyl, cyanomethylaminocarbonylmethyl, or haloethylaminocarbonylethyl;

[0268] R 5 is hydrogen, alkyl or haloalkyl;

[0269] R 6 is hydrogen, alkyl or haloalkyl;

[0270] or R 3 and R 4 Together they form a substituent selected from:

[0271]

[0272] or the use of a salt or solvate thereof in the preparation of a medicament for treating or protecting sheep from infestation by Bovicola ovis chewing lice following a single oral administration of a composition comprising an effective amount of at least one isoxazoline compound of formula (I) to sheep of any wool length.

[0273] 55. The use according to paragraph 54, wherein the medicament is for protecting sheep from infestation by Bovicola ovis chewing lice.

[0274] 56. The use according to paragraph 54 or 55, wherein the isoxazoline compound of formula (I) is flurellanil.

[0275] 57. The use according to any of paragraphs 54-56, wherein the effective amount of the isoxazoline compound is 0.5-3 mg / kg of animal body weight.

[0276] 58. The use according to any of paragraphs 54-57, wherein the composition is administered as an oral drench.

[0277] 59. The use according to any of paragraphs 54 to 58, wherein the composition is applied once to a flock of sheep having at least one sheep diagnosed with chewing lice infestation.

[0278] 60. The use according to paragraph 59, wherein the composition is applied once within 24 hours after shearing (just after shearing).

[0279] 61. The use according to paragraph 59, wherein the composition is applied once within a period of >24 hours after shearing to 6 weeks after shearing (short hair).

[0280] 62. The use according to paragraph 59, wherein the composition is applied once > 6 weeks after shearing (hair growing).

[0281] 63. The use according to any of paragraphs 54-62, wherein the effective amount of the isoxazoline compound is sufficient to eliminate an existing chewing lice infestation within 15 days of administration.

[0282] 64. The use according to any of paragraphs 54-63, wherein the effective amount of the isoxazoline compound is sufficient to eliminate viable chewing lice eggs from the treated animal within 42 days after administration.

[0283] 65. The use according to any of paragraphs 54-64, wherein a single oral administration of an effective amount of the isoxazoline compound is sufficient to eliminate all live lice and live eggs from the treated animal when studied 140 days after treatment.

[0284] 66. The use according to any of paragraphs 54-65, wherein the effective amount of the isoxazoline compound is sufficient to protect sheep from chewing lice infestation for at least 2 weeks after a single oral administration.

[0285] 67. The use according to paragraph 66, wherein the effective amount of the isoxazoline compound is sufficient to protect sheep from chewing lice infestation for at least 6 weeks after a single oral administration.

[0286] 68. The use according to any of paragraphs 54-67, wherein the chewing louse is resistant to any of organophosphates, synthetic pyrethroids, neonicotinoids, spinosad, or benzoylphenyl urea compounds.

[0287] 69. The use according to any of paragraphs 54-68, wherein the composition comprises another active pharmaceutical ingredient.

[0288] 70. The use according to paragraph 69, wherein the composition comprises at least one endoparasitic drug.

[0289] 71. A composition comprising an effective amount of at least one isoxazoline compound of formula (I) as defined in paragraph 54 or 56, or a salt or solvate thereof, when used to eliminate chewing lice parasite infestations in sheep and / or for protecting sheep from chewing lice infestations, wherein the composition is orally administered to sheep of any fleece length.

[0290] 72. A method of treating sheep diagnosed or suspected of being infested with chewing lice parasites, the method comprising administering to the sheep an effective amount of at least one isoxazoline compound of formula (I) as defined in paragraph 54 or 56, or a salt or solvate thereof, irrespective of the length of their fleece using a single oral administration.

[0291] 73. A method of protecting sheep from infestation by chewing lice comprising administering to the sheep, regardless of the length of their fleece, an effective amount of an isoxazoline compound of formula (I) or a salt or solvate thereof as defined in paragraph 54 or 56 using a single oral administration.

[0292] It should be understood that the reference to a prior art document herein does not constitute an admission that the document forms part of the common general knowledge in the art, in Australia or any other country.

[0293] In the following paragraphs and in the foregoing description of the invention, unless the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "include" or "comprising" are used in an inclusive sense, that is, specifying the presence of stated features but not excluding the presence or addition of other features in various embodiments of the invention.

[0294] Preferred embodiments according to the present invention are defined below. The preferred embodiments are preferably used alone or in combination. In addition, it should be understood that the following preferred embodiments relate to all aspects of the present invention, i.e., compositions for use, methods for treatment or protection, and uses for the manufacture of medicaments. Example

[0295] Background Embodiment

[0296] Pharmacokinetic studies (topical, oral and subcutaneous administration)

[0297] The aim of this study was to determine the pharmacokinetic profile of flurellan following a single topical, oral or subcutaneous (SC) administration to freshly shorn sheep. The nominal dose for all formulations was 3 mg / kg body weight (bw).

[0298] Four groups of six young adult healthy Merino sheep (within 24 hours of shearing) (3 females, 3 castrated males) were given a single dose of flurellana at a nominal dose of 3 mg flurellana / kg body weight, topically (Group 1: pour-on 1; Group 2: pour-on 2), orally (Group 3) or subcutaneously - SC (Group 4).

[0299] Blood samples were collected 84 days after administration, and plasma samples were analyzed for flurellanil.

[0300] After topical application, there was a rapid (over 5 days) and slow (over 12 days) increase to peak concentration in Group 2 and Group 1, respectively.

[0301] Then, at the last collection time point, the concentration dropped to a value below 1 ng / mL.

[0302] After oral administration, rapid absorption of S-flurane was observed within the first day after dosing. The peak was ca. 100 ng / mL. Then, the concentration dropped sharply, and by day 21 after dosing, the concentration of all subjects was below the LLOQ.

[0303] After SC administration, the mean concentration was observed to increase slowly to a peak concentration at 12 days after dosing. Then, the mean concentration gradually decreased toward the last collection time point (i.e., 84 days after dosing).

[0304] The pharmacokinetic parameters reflected the differences observed in the concentration-time curves after topical, oral, and SC administration. Higher AUC and C were observed in Group 3 (oral). max And a shorter T max , whereas a higher MRT was observed in group 4 (SC) last .

[0305] The average concentration of S-flurana in blood is Figure 2 shown.

[0306] Example 1

[0307] Effect on 9-month wool growing sheep

[0308] In this study, the efficacy of flurellanal was evaluated against sheep body lice (Bovicola ovis) infestation on Merino sheep with 9 months wool growth when administered orally once at doses of 2.0 and 3.0 mg / kg body weight. Plasma samples as well as tissue samples were also collected at the end of the study.

[0309] Twenty-eight (28) medium wool Merino ewes with a heavy (>5 lice / 10 cm section) diazinon-resistant sheep body lice infestation were divided into groups of 7 animals so that each group had a similar average lice load.

[0310] On day 0, flurellana was administered to sheep in groups 2 and 3 at 2.0 and 3.0 mg flurellana / kg body weight, respectively. The doses were administered orally via the dorsum of the tongue. Group 1 was not treated as a negative control.

[0311] Pre-treatment lice counts were performed on day -1 and used to assign sheep to treatment groups. Post-treatment lice counts were performed at 3, 7, 14, 21, 42, 70, 84, 112 and 140 days ± 1 day after treatment.

[0312] Lice counts were performed according to the World Association for the Advancement of Veterinary Parasitology (WAAVP) “Guidelines for evaluating the efficacy of ectoparasiticides against biting lice, sucking lice and sheepkeds on ruminants” and the APVMA preamble to these guidelines.

[0313] Twenty (20) sites on each side of the body were examined by opening the fleece approximately 10 cm and counting all live lice seen. The total counts from forty (40) sites constituted the body count for each animal.

[0314] In the final lice count on day 140, the number of sites examined was doubled to increase the sensitivity of the count.

[0315] The sites examined were spaced so that they represented the entire area of ​​the body covered by wool on each side of the sheep. At each post-treatment lice count, the number of live lice eggs was also counted and recorded.

[0316] The efficacy proportions for each treatment group at each evaluation time were calculated using the geometric mean lice counts and the Henderson-Tilton formula:

[0317] Efficacy ratio = (1-(Ta / Ca)×(Cb / Tb))×100

[0318] in:

[0319] Ta = average number of lice in the treated group after treatment.

[0320] Ca = mean number of lice in the negative control group after treatment.

[0321] Tb = mean number of lice in the treatment group before treatment.

[0322] Cb = mean number of lice in the negative control group before treatment.

[0323] Treatment groups receiving the 2 and 3 mg / kg dose rates achieved 100% efficacy 13 days after treatment and maintained this level of efficacy until the final lice count on Day 140. From Day 41 until the last count on Day 140, no live lice eggs were detected at the 2 and 3 mg / kg dose rates.

[0324] Example 2

[0325] Effect on freshly shorn sheep

[0326] In this study, the efficacy of flurellanal was evaluated against an infestation of sheep body lice (Bovicola ovis) on freshly shorn Merino sheep when administered orally once at doses of 0.5, 1.0, 1.5 and 2.0 mg / kg body weight.

[0327] Thirty-five (35) Merino sheep with heavy (>5 lice / 10 cm section) body lice infestation were assigned to 5 groups of 7 animals each so that each group had a similar average lice load. On day 0, flurellana was administered to sheep in groups 2, 3, 4 and 5 at 0.5, 1.0, 1.5 and 2.0 mg flurellana / kg body weight, respectively, within 24 hours after shearing. The doses were administered orally via the dorsum of the tongue. Group 1 was not treated as a negative control.

[0328] Pre-treatment lice counts were performed on day -1 and used to assign sheep to treatment groups. Post-treatment lice counts were performed 3, 7, 14, 21, 42, 84, 112 and 140 days after treatment ± 1 day / . Lice counts were performed as described in Example 1.

[0329] Dose rates of 0.5, 1.0, 1.5 and 2.0 mg / kg achieved 100% efficacy 14 days after treatment until final counts on Day 112. Dose rates of 1.0, 1.5 and 2.0 mg / kg achieved 100% efficacy 7 days after treatment, and the efficacy of the dose rate of 0.5 mg / kg was greater than 99%. No live lice eggs were detected at dose rates of 0.5, 1.0, 1.5 and 2.0 mg / kg from Day 21 until final counts on Day 112. No live lice eggs were detected at the dose rate of 2.0 mg / kg from Day 14 until final counts on Day 112.

[0330] Example 3

[0331] Effect on long-haired sheep

[0332] In this study, the efficacy of flurellanal was evaluated against infestations of sheep body lice (Bovicola ovis) in Merino sheep with wool growth of 3, 6 and 9 months when administered orally once at doses of 1.5 and 2.0 mg / kg body weight.

[0333] 30 Merino sheep / fleece lengths with moderate to severe (1->5 lice / 10 cm section) body lice infestation were assigned to three groups of 10 animals each, so that each group had a similar average lice load. Fluorellana was administered to each group of sheep at each fleece length at 1.5 and 2.0 mg Fluorellana / kg body weight, respectively. The doses were administered orally via the dorsum of the tongue. One group of each fleece length was left untreated as a negative control.

[0334] Pre-treatment lice counts were performed on day -1 and used to assign sheep to treatment groups. Post-treatment lice counts were performed at 7, 14, 21, 42, 90 and 140 days ± 1 day after treatment or until the next annual shearing, whichever occurred first. Lice counts were performed as described in Example 1.

[0335] At 14 days post-treatment, the 1.5 and 2.0 mg / kg dose rates achieved 100% efficacy at each wool length. From day 42 onwards, no live lice eggs were detected at the 1.5 and 2.0 mg / kg dose rates at 6 and 9 month wool lengths.

[0336] Example 4

[0337] Persistence assay

[0338] In this study, the persistent efficacy of flurellanal was evaluated against infestations of sheep body lice (Bovicola ovis) on Merino sheep with 2 months of wool growth when administered orally once at doses of 1.5 and 2.0 mg / kg body weight.

[0339] 42 lice-free Merino sheep were divided into 6 groups of 7 animals each, so that each group had a similar average body weight. Fluorella was administered to the sheep in two groups at 1.5 and 2.0 mg fluorella / kg body weight. The doses were administered orally via the dorsum of the tongue. Two groups were not treated as negative controls.

[0340] Starting from days 0-7 and 7-14 after treatment, a group of untreated negative control sheep and a group of sheep treated with 1.5 and 2.0 mg / kg were challenged with lice by close contact with lice-infested sheep and manual transfer of lice. After challenge, lice counts were performed at 7, 14, 21, 42 and 84 days ± 1 day after challenge.

[0341] No lice or live lice eggs were found on sheep treated at dose rates of 1.5 and 2.0 mg / kg at 14, 21, 42 and 84 days ± 1 day post challenge.

Claims

1. Use of flurellana or its salts in the preparation of a medicament for treating or protecting sheep from infestation by Bovicola ovis chewing lice, regardless of the length of their fleece, following a single oral administration of a composition comprising an effective amount of flurellana to sheep; the composition being administered as an oral drench, the effective amount of flurellana being 0.5 to 3 mg / kg of the animal's body weight.

2. The use according to claim 1, wherein the medicament is used to protect sheep from infestation by Bovicola ovis chewing lice.

3. Use according to claim 1 or 2, wherein the composition is applied once to a flock of sheep having at least one sheep diagnosed with chewing lice infestation.

4. The use according to claim 3, wherein the composition is applied once within 24 hours after shearing.

5. The use according to claim 3, wherein the composition is applied once within a period of >24 hours after shearing to 6 weeks after shearing.

6. Use according to claim 3, wherein the composition is applied once > 6 weeks after shearing.

7. The use according to claim 1, wherein the effective amount of flurellanal is sufficient to eliminate an existing chewing lice infestation within 15 days after administration.

8. The use according to claim 1, wherein the effective amount of flurellanal is sufficient to eliminate viable chewing lice eggs from the treated animal within 42 days after administration.

9. The use according to claim 1, wherein a single oral administration of the effective amount of flurellana is sufficient to eliminate all live lice and live eggs from the treated animals when studied 140 days after treatment.

10. The use of claim 1, wherein the effective amount of flurellana is sufficient to protect sheep from chewing lice infestation for at least 2 weeks following a single oral administration.

11. The use according to claim 10, wherein the effective amount of flurellana is sufficient to protect sheep from chewing lice infestation for at least 6 weeks after a single oral administration.

12. The use according to claim 1, wherein the chewing louse is resistant to any one of organophosphates, synthetic pyrethroids, neonicotinoids, spinosad or benzoylphenyl urea compounds.